<DOC>
	<DOCNO>NCT02637323</DOCNO>
	<brief_summary>This open-label , single administration study 40 mg FX006 Triamcinolone Acetonide Injectable Suspension , USP ( refer TCA IR protocol ) conduct male female patient Osteoarthritis ( OA ) knee .</brief_summary>
	<brief_title>Study Characterize Systemic PK Local Extent Duration Exposure TCA From FX006 Patients With OA Knee</brief_title>
	<detailed_description>Approximately 60 patient OA knee ( 10 per Cohort ) treat single 5mL intra-articular ( IA ) injection 40 mg FX006 single 1 mL injection 40 mg TCA IR . Patients enrol sequentially one six cohort . Cohorts A E receive 40 mg FX006 . Cohort F receive 40 mg TCA IR . Synovial Fluid Visits follow cohort : Cohort A : 20 Weeks , Cohort B : 16 Weeks , Cohort C : 12 Weeks , Cohort D F : 6 Weeks , Cohort E : 1 Week . Each patient evaluate safety his/her participation study plasma synovial fluid collect drug concentration measurement .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<criteria>Written consent participate study Willingness ability comply study procedure visit schedule ability follow verbal write instruction Symptoms associate OA knee ≥ 6 month prior Screening ( patient report acceptable ) Currently meet American College Rheumatology ( ACR ) Criteria ( clinical radiological ) OA Index knee pain &gt; 15 day last month ( report patient ) Body mass index ( BMI ) ≤ 40 kg/m2 Ambulatory good general health Fibromyalgia , Reiter 's syndrome , rheumatoid arthritis , psoriatic arthritis , ankylose spondylitis , arthritis associate inflammatory bowel disease History infection index knee joint Clinical sign symptom active knee infection crystal disease index knee within 1 month Screening Presence surgical hardware foreign body index knee Unstable joint within 12 month Screening IA corticosteroid ( investigational market ) joint within 6 month Screening IA hyaluronic acid ( investigational market ) index knee within 6 month Screening Intravenous Intramuscular corticosteroid ( investigational market ) within 3 month Screening Oral corticosteroid ( investigational market ) within 1 month Screening Inhaled , intranasal topical corticosteroid ( investigational market ) within 2 week Screening Any IA investigational drug/biologic use within 6 month Screening 5 halflives ( whichever longer ) Prior use FX006 Women childbearing potential use effective contraception pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Knee</keyword>
	<keyword>Pain</keyword>
	<keyword>Steroid</keyword>
	<keyword>Intra-articular</keyword>
	<keyword>Injection</keyword>
</DOC>